Carcinoma of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Technical advance in targeted NGS analysis enables identification of lung cancer risk-associated low frequency TP53, PIK3CA, and BRAF mutations in airway epithelial cells.
|
31711466 |
2019 |
Carcinoma of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Impact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-mutant Lung Cancer.
|
30224342 |
2019 |
Carcinoma of lung
|
0.700 |
Biomarker
|
disease |
BEFREE |
BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors.
|
29723688 |
2018 |
Carcinoma of lung
|
0.700 |
Biomarker
|
disease |
BEFREE |
A group of thoracic oncology experts in the field of thoracic oncology met to describe the standard for biomarker testing for lung cancer in the Canadian context, focusing on evidence-based recommendations for standard-of-care testing for <i>EGFR</i>, anaplastic lymphoma kinase (<i>ALK</i>), <i>ROS1</i>, <i>BRAF V600</i> and programmed death-ligand (PD-L1) at the time of diagnosis of advanced disease and <i>EGFR T790M</i> upon progression.
|
29507487 |
2018 |
Carcinoma of lung
|
0.700 |
Biomarker
|
disease |
BEFREE |
The novel BRAF Thr599dup gene mutation, for which the repeat amino acid-tyrosine is inserted between the 599th amino acid and the 600th amino acid in exon 15 of BRAF, was identified by next-generation sequencing (NGS) during routine clinical care in a lung carcinoma sample from an Asian never-smoker.
|
30019008 |
2018 |
Carcinoma of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
These results indicate that AZ628 has greater potential than Dabrafenib, both as a single agent and combined with Trametinib, for the treatment of non-V600 BRAF mutant lung cancer.
|
29662630 |
2018 |
Carcinoma of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Economic analysis of BRAF gene mutation testing in real world practice using claims data: costs of single gene versus panel tests in patients with lung cancer.
|
29516752 |
2018 |
Carcinoma of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Accordingly, the combination of MEK inhibitor with EGFR inhibitor was effective at shrinking tumors in mouse model of BRAF non-V600E mutant lung cancer.
|
29348459 |
2018 |
Carcinoma of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.
|
28203297 |
2017 |
Carcinoma of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
BRAF mutated lung cancer is a genetically distinct subtype that occurs in 2-5% of non-small cell lung carcinomas (NSCLC).
|
28625649 |
2017 |
Carcinoma of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib.
|
28947956 |
2017 |
Carcinoma of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Radiogenomic evaluation of lung cancer - Are there imaging characteristics associated with lung adenocarcinomas harboring BRAF mutations?
|
28012356 |
2017 |
Carcinoma of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Since hypoxic microenvironments select for tumor cells with diminished therapeutic response, we investigated whether hypoxia unequally increases resistance to 3-BrPA in wt p53 MelJuso melanoma harbouring (Q61L)-mutant NRAS and wt BRAF, C8161 melanoma with (G12D)-mutant KRAS (G464E)-mutant BRAF, and A549 lung carcinoma with a KRAS (G12S)-mutation.
|
27863474 |
2016 |
Carcinoma of lung
|
0.700 |
Biomarker
|
disease |
BEFREE |
One of our predicted biomarker pairs, a mutation in the BRAF gene and upregulated expression of the PIM1 gene, was experimentally validated to benefit from a therapy combining BRAF inhibitor and PIM1 inhibitor in lung cancer.
|
26916442 |
2016 |
Carcinoma of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
ATM loss also enhances the sensitivity of KRAS- or BRAF-mutant lung cancer cells to MEK inhibition.
|
27922010 |
2016 |
Carcinoma of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer.
|
27834212 |
2016 |
Carcinoma of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Our clinical data suggest that BRAF mutations define specific subsets of patients with NSCLC; while their oncogenic nature is yet to be established in lung cancer, especially for non-V600E mutations, the value of BRAF mutations to predict the efficacy of targeted agents remains unclear.
|
26711930 |
2016 |
Carcinoma of lung
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Recent evidence shows that BRAF-activated non-coding RNA (BANCR) acts as a critical role in the proliferation and metastasis in malignant melanoma and lung cancer; however, little is known about the significance of lncRNA BANCR in retinoblastoma.
|
25894373 |
2015 |
Carcinoma of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We developed a highly sensitive LUNG CANCER (LC)-biochip approach for the detection of the most common EGFR, KRAS, PIK3CA, and BRAF gene mutations.
|
25153497 |
2015 |
Carcinoma of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We conducted a retrospective multicenter cohort study in Europe of patients with advanced BRAF-mutant lung cancer treated with known BRAF inhibitors.
|
26200454 |
2015 |
Carcinoma of lung
|
0.700 |
Biomarker
|
disease |
BEFREE |
Jointly, our results suggest a potential role of the novel BRAF fusion in lung cancer development and therapy.
|
25985019 |
2015 |
Carcinoma of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
V-Raf Murine Sarcoma Viral Oncogene Homolog B (BRAF) mutated lung cancer is relatively aggressive and is resistant to currently available therapies.
|
25706985 |
2015 |
Carcinoma of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Combined genomic and proteomic analyses demonstrated infrequent alteration of validated lung cancer targets (including the absence of BRAF mutations in TTF1-negative LUAD), but identified novel potential targets for TTF1-negative LUAD, including KEAP1/Nrf2 and DNA repair pathways.
|
25878335 |
2015 |
Carcinoma of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.
|
25273224 |
2015 |
Carcinoma of lung
|
0.700 |
Biomarker
|
disease |
BEFREE |
Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer.
|
24550319 |
2014 |